Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 1136273 | 9.19 |
09:34 ET | 1103185 | 8.855 |
09:36 ET | 582425 | 8.9913 |
09:38 ET | 547821 | 9.19 |
09:39 ET | 621516 | 8.86 |
09:41 ET | 695185 | 8.62 |
09:43 ET | 342786 | 8.535 |
09:45 ET | 293882 | 8.74 |
09:48 ET | 338963 | 8.96 |
09:50 ET | 431096 | 8.9 |
09:52 ET | 210483 | 8.85 |
09:54 ET | 537408 | 8.9577 |
09:56 ET | 413587 | 9.09 |
09:57 ET | 350346 | 8.79 |
09:59 ET | 255060 | 8.78 |
10:01 ET | 363288 | 8.549 |
10:03 ET | 286395 | 8.3301 |
10:06 ET | 190326 | 8.47 |
10:08 ET | 267695 | 8.4305 |
10:10 ET | 174996 | 8.41 |
10:12 ET | 180033 | 8.27 |
10:14 ET | 300025 | 8.37 |
10:15 ET | 365258 | 8.0799 |
10:17 ET | 284316 | 7.87 |
10:19 ET | 476562 | 7.76 |
10:21 ET | 252077 | 7.8115 |
10:24 ET | 212936 | 8.03 |
10:26 ET | 181964 | 8.1699 |
10:28 ET | 203936 | 8.055 |
10:30 ET | 68028 | 8.105 |
10:32 ET | 132642 | 7.85 |
10:33 ET | 74017 | 7.99 |
10:35 ET | 129617 | 7.88 |
10:37 ET | 117672 | 8.08 |
10:39 ET | 313094 | 8.35 |
10:42 ET | 240498 | 8.1796 |
10:44 ET | 113496 | 8.3 |
10:46 ET | 127389 | 8.36 |
10:48 ET | 118808 | 8.2844 |
10:50 ET | 88773 | 8.195 |
10:51 ET | 424144 | 8.41 |
10:53 ET | 140760 | 8.3611 |
10:55 ET | 192270 | 8.425 |
10:57 ET | 184541 | 8.3793 |
11:00 ET | 88197 | 8.3744 |
11:02 ET | 116886 | 8.4332 |
11:04 ET | 138231 | 8.33 |
11:06 ET | 349067 | 8.395 |
11:08 ET | 228179 | 8.5401 |
11:09 ET | 286695 | 8.705 |
11:11 ET | 178633 | 8.6599 |
11:13 ET | 185125 | 8.685 |
11:15 ET | 101070 | 8.74 |
11:18 ET | 180764 | 8.895 |
11:20 ET | 223868 | 8.715 |
11:22 ET | 162361 | 8.72 |
11:24 ET | 79554 | 8.815 |
11:26 ET | 106616 | 8.9 |
11:27 ET | 55803 | 8.875 |
11:29 ET | 134238 | 8.895 |
11:31 ET | 185686 | 8.91 |
11:33 ET | 185492 | 8.5701 |
11:36 ET | 206305 | 8.565 |
11:38 ET | 128580 | 8.5411 |
11:40 ET | 49417 | 8.61 |
11:42 ET | 93054 | 8.7 |
11:44 ET | 106924 | 8.7501 |
11:45 ET | 189343 | 8.85 |
11:47 ET | 123750 | 8.8737 |
11:49 ET | 32648 | 8.875 |
11:51 ET | 73364 | 8.895 |
11:54 ET | 83140 | 8.815 |
11:56 ET | 63759 | 8.894 |
11:58 ET | 101655 | 8.951 |
12:00 ET | 409526 | 8.8853 |
12:02 ET | 155227 | 8.851 |
12:03 ET | 75318 | 8.835 |
12:05 ET | 64280 | 8.765 |
12:07 ET | 61893 | 8.83 |
12:09 ET | 65737 | 8.75 |
12:12 ET | 42261 | 8.82 |
12:14 ET | 78363 | 8.895 |
12:16 ET | 336432 | 9.215 |
12:18 ET | 244045 | 9.0401 |
12:20 ET | 192729 | 9.185 |
12:21 ET | 153926 | 9.21 |
12:23 ET | 148076 | 9.1012 |
12:25 ET | 106583 | 9.027 |
12:27 ET | 145906 | 8.9201 |
12:30 ET | 141989 | 8.92 |
12:32 ET | 55813 | 8.97 |
12:34 ET | 85554 | 8.9599 |
12:36 ET | 147002 | 9.005 |
12:38 ET | 56932 | 8.959 |
12:39 ET | 57793 | 8.87 |
12:41 ET | 34267 | 8.9125 |
12:43 ET | 186427 | 8.74 |
12:45 ET | 56339 | 8.85 |
12:48 ET | 74919 | 8.79 |
12:50 ET | 72540 | 8.8996 |
12:52 ET | 84891 | 8.675 |
12:54 ET | 73711 | 8.6999 |
12:56 ET | 35774 | 8.7601 |
12:57 ET | 32515 | 8.77 |
12:59 ET | 78461 | 8.7801 |
01:01 ET | 27839 | 8.76 |
01:03 ET | 37466 | 8.854 |
01:06 ET | 25522 | 8.75 |
01:08 ET | 44366 | 8.9 |
01:10 ET | 30193 | 8.9 |
01:12 ET | 43062 | 8.7401 |
01:14 ET | 80247 | 8.681 |
01:15 ET | 75165 | 8.7111 |
01:17 ET | 42035 | 8.56 |
01:19 ET | 38919 | 8.58 |
01:21 ET | 60505 | 8.6353 |
01:24 ET | 27823 | 8.655 |
01:26 ET | 21066 | 8.5401 |
01:28 ET | 19532 | 8.64 |
01:30 ET | 58159 | 8.66 |
01:32 ET | 37140 | 8.705 |
01:33 ET | 35185 | 8.665 |
01:35 ET | 21956 | 8.75 |
01:37 ET | 14454 | 8.7101 |
01:39 ET | 30736 | 8.6 |
01:42 ET | 28566 | 8.62 |
01:44 ET | 22653 | 8.6188 |
01:46 ET | 22871 | 8.605 |
01:48 ET | 22621 | 8.585 |
01:50 ET | 52855 | 8.665 |
01:51 ET | 38832 | 8.6332 |
01:53 ET | 35135 | 8.668 |
01:55 ET | 12963 | 8.6 |
01:57 ET | 37934 | 8.6125 |
02:00 ET | 41571 | 8.635 |
02:02 ET | 46274 | 8.63 |
02:04 ET | 46852 | 8.6301 |
02:06 ET | 28633 | 8.675 |
02:08 ET | 45604 | 8.6401 |
02:09 ET | 17675 | 8.6799 |
02:11 ET | 83585 | 8.6997 |
02:13 ET | 92572 | 8.675 |
02:15 ET | 121409 | 8.795 |
02:18 ET | 75735 | 8.764 |
02:20 ET | 42097 | 8.775 |
02:22 ET | 134576 | 8.82 |
02:24 ET | 143347 | 8.97 |
02:26 ET | 84067 | 8.89 |
02:27 ET | 64657 | 8.865 |
02:29 ET | 103037 | 8.83 |
02:31 ET | 50369 | 8.785 |
02:33 ET | 269357 | 8.75 |
02:36 ET | 43635 | 8.78 |
02:38 ET | 40840 | 8.7139 |
02:40 ET | 57480 | 8.705 |
02:42 ET | 60413 | 8.8786 |
02:44 ET | 65218 | 8.885 |
02:45 ET | 31566 | 8.88 |
02:47 ET | 84837 | 8.98 |
02:49 ET | 142531 | 9.074 |
02:51 ET | 143207 | 8.9751 |
02:54 ET | 94231 | 8.95 |
02:56 ET | 158987 | 9.0977 |
02:58 ET | 112516 | 9.134 |
03:00 ET | 105096 | 9.125 |
03:02 ET | 176295 | 8.8901 |
03:03 ET | 49639 | 8.985 |
03:05 ET | 111695 | 8.85 |
03:07 ET | 81359 | 8.96 |
03:09 ET | 95571 | 8.7793 |
03:12 ET | 97844 | 8.67 |
03:14 ET | 280463 | 8.51 |
03:16 ET | 128042 | 8.62 |
03:18 ET | 89397 | 8.61 |
03:20 ET | 56096 | 8.68 |
03:21 ET | 45113 | 8.7988 |
03:23 ET | 73837 | 8.56 |
03:25 ET | 165121 | 8.815 |
03:27 ET | 168555 | 8.675 |
03:30 ET | 552445 | 8.755 |
03:32 ET | 9152 | 8.685 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 6.1B | -52.4x | --- |
Revolution Medicines Inc | 6.3B | -10.2x | --- |
Cytokinetics Inc | 5.6B | -9.0x | --- |
Viking Therapeutics Inc | 6.9B | -66.9x | --- |
BridgeBio Pharma Inc | 5.2B | -8.7x | --- |
Madrigal Pharmaceuticals Inc | 5.0B | -10.2x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.03 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -52.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.